pS2 and PAI-1 in ovarian cancer: Correlation to pathohistological parameters

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 679-683

  Speiser, Paul ^a   Mayerhofer, Klaus ^a   Kucera, Elisabeth ^a   Roch, Gerhard ^a   Mittelböck, Martina ^a   Gitsch, Gerald ^a   Zeillinger, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ovarian cancer; PAI 1; pS2

Indexed keywords

CELL PROTEIN; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; PROTEIN PS2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA; CYTOSOL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0031048541     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lingeman CH: Etiology of cancer of the ovary: a review. J Natl Cancer Inst 53: 1603-1618, 1974.
2. Schottenfeld D, and Berg J: Incidence of multiple primary cancer. J Natl Cancer Inst 46: 161-170, 1971.
3. Masiakowski P, Breathnach R, Bloch J, Cannon K, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res 19: 7895-7903, 1982.
4. Berry M, Nunez A-M, Chambon P: Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U.S.A. 86: 1218-1222, 1989.
5. Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P and Chambon P: Sequence of the pS2 mRNA induced by estrogen in the human breast-cancer cell line MCF-7. Nucleic Acids Res 12: 2861-2878, 1984.
6. Rio M-C, Bellocq JP, Daniel JY, Tomosetto C, Lathe R, Chenard MP, Batzenschlager N and Chambon P: Breast cancer-associated pS2 protein synthesis and secretion by normal stomach mucosa. Science 241: 705-708, 1988.
7. Speiser P, Stolzlechner J, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, and Zeillinger R: pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Res 14: 2125-2130, 1994.
8. Foekens JA, Van Putten WLJ, Portengen H, De Koning HYWCM, Thirion B, Alexieva-Figusch J and Klijn JGM: Prognostic value of pS2 and Cathepsin D in 710 human primary breast tumors: Multivariate analysis, J Clin Oncol 11: 899-908, 1993.
9. Predine J. Spyratos F, Prud' Homme JF, Andrieus C, Hacene K, Brunet M, Pallud C and Migrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancer, benign tumors, and normal breast tissue. Correlation with prognosis and adjuvant hormone therapy. Cancer 69: 2116-2123, 1992.
10. Foekens JA, Rio MC, Seguin P, Van Putten WLJ, Fauque J, Nap M, Klijn JGM and Chambon P: Prediction of relapse and survival in breast cancer by pS2 protein status. Cancer Res 50: 3832-3837, 1990.
11. Thompson AM, Hawnins RA, Elton RA, Steel CM, Chetty U and Carter DC: pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 68:93-96, 1993.
12. Gion M, Mione R, Papagallo GL, Gatti C, Nascimben O, Bari M, Leon AE, Vinante O and Bruscagnin G: pS2 in breast cancer-alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 68: 347-379, 1993.
13. Piggott NH, Henry JA, May FEB and Westley BR: Antipeptide antibodies against the PNR-2 oestrogen-regulated protein of human breast cancer cells and detection of PNR-2 expression in normal tissues by immunhistochemistry. J Pathol 163: 95, 1991.
14. Luqmani Y, Bennett C, Paterson I et al: Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 44: 806, 1989.
15. Wysocki SJ, Hahnel E, Masters A, Smith V, McCartney AJ and Hahnel R: Detection of pS2 messenger RNA in gynecological cancers. Cancer Res 50:1800-1802, 1990.
16. Henry JA, Bennett MK, Piggott NH, Levett DL, May FEB, Westley BR: Expression of the pNR-2/pS2 protein in diverse human epithelial tumors. Br J Cancer 64: 677-682, 1991.
17. Dante R, Ribieras ST, Baldassini S. Martin V, Benzerara O, Bouteille C, Bremond A, Frappart L, Rio M-C, Lasne Y: Expression of an estrogen -induced breast cancer-associated protein (pS2) in benign and malignant human ovarian cysts. Lab Invest 71: 188-193, 1994.
18. Camiolo SM, Markus G, Piver MS: Plasminogen activator contest of gynecological tumors and their metastases. Gynecol Oncol 26: 364-373, 1987.
19. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ: Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335: 108, 1990.
20. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P: Urokinase plasminogen activator, a new and independent prognositic marker in breast cancer. Cancer Res 50: 6827-6829, 1990.
21. Janicke F, Schmitt M, Ulm K, Gössner W, Graeff H: Urokinase type plasminogen activator antigen and early relapse in breast cancer. Lancet 2(8670): 1049, 1989.
22. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Fache L, Graeff H: Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance. Biol-Chem-Hoppe-Seyler 373: 611-622, 1992.
23. Sumiyoshi K, Baba S, Sakaguchi S, Urano T, Takada Y, Takada A: Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cnacer: Possible roles in tumor progression and metastases. Thrombosis Res 63: 59-71, 1991.
24. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Grossner W, Graeff H: Urokinase-type plasminogen -activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 69: 69-78, 1990.
25. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA: Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-214, 1992.
26. Sumiyoshi K, Serizawa K, Urano T, Takada A, Baba S: Plasminogen activator system in human breast cancer. Int J Cancer 50: 345-348, 1992.
27. Mayerhofer K, Stolzlechner J, Yildiz S, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeillinger R, Speiser P: Plasminogen activator inhibitor 1 and prognosis in carcinoma of the breast. Geburtsh u Frauenheilk 561: 23-27, 1996.
28. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase-type plasminogen activator antigen (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993.
29. Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EKO, Lijnen HR, Burtin P: The plasminogen-activation system in ovarian tumors. Int J Cancer 55: 27-31, 1993.
30. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Sanicke F, Graeff H: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409, 1994.
31. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Janicke F, Hofler H, Graeff H: Primary tumor and metastasis in ovarian cancer differ in their content of Urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55(18): 3958-3963, 1995.